FTN Equity Starts Mylan Labs (MYL) at Neutral
More News related to MYL
- Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
- Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
More News related to New Coverage
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
FTN Equity initiates coverage on Mylan Labs (NYSE: MYL) with a Neutral rating.
For more analyst ratings on MYL click here.
Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic, brand, and branded generic pharmaceutical products and active pharmaceutical ingredients (APIs).
Related Categories
New CoverageStocks Mentioned
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
